JAMONY
ACHN

Jacob Asset Management of New York’s Achillion Pharmaceuticals ACHN Stock Holding History

Jacob Asset Management of New York’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		$276K Buy
91,389
+38,000
+71% +$260K 0.34% 81
2013
Q2 		$437K Buy
+53,389
New +$408K 0.59% 52

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jacob Asset Management of New York's ACHN Position: Q3 2013 in Review

Jacob Asset Management of New York increased its Achillion Pharmaceuticals (ACHN) stake by 71% in Q3 2013, buying an estimated $260K and bringing the position to 91,389 shares worth $276K. The position accounts for 0.34% of the portfolio, ranked #81.

Jacob Asset Management of New York first reported a position in ACHN in Q2 2013 and has held it in 2 quarters since. The position peaked at $437K in Q2 2013. 102 funds tracked by Wall St. Rank hold ACHN as of Q3 2013.

  • Jacob Asset Management of New York held 91,389 shares of Achillion Pharmaceuticals worth $276K as of Q3 2013.
  • Jacob Asset Management of New York bought 38,000 Achillion Pharmaceuticals shares in Q3 2013, an estimated $260K.
  • Achillion Pharmaceuticals made up 0.34% of Jacob Asset Management of New York's portfolio in Q3 2013, its #81 holding.
  • Jacob Asset Management of New York first reported a position in Achillion Pharmaceuticals in Q2 2013 and has held it in 2 quarters since.
  • Jacob Asset Management of New York's Achillion Pharmaceuticals position peaked at $437K in Q2 2013.
  • 102 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2013.

Based on Jacob Asset Management of New York's 13F filing for Q3 2013, filed 14 Nov 2013.